Latest Influenza vaccine Stories
MIT study identifies influenza viruses circulating in pigs and birds that could pose a risk to humans. In the summer of 1968, a new strain of influenza appeared in Hong Kong. This strain, known as H3N2, spread around the globe and eventually killed an estimated 1 million people. A new study from MIT reveals that there are many strains of H3N2 circulating in birds and pigs that are genetically similar to the 1968 strain and have the potential to generate a pandemic if they leap to...
NES ZIONA, Israel, May 13, 2013 /PRNewswire/ -- NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East Asia. This collaboration is a part of NanoPass's long-term commitment to improve Global Health by providing access to its vaccine delivery devices....
BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013. Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period in 2012. Total operating expenses were $8.1 million compared to $5.9 million. The net loss attributable to common stockholders was $8.8 million, or $0.06 per share, compared to $8.3 million, or $0.06 per...
-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9- QUEBEC CITY, May 8, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is...
GAITHERSBURG, Md., May 4, 2013 /PRNewswire/ -- MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013. These abstracts advance the body of existing data and knowledge around influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued commitment to patient health. MedImmune posters to be presented at...
Ready to Manufacture a Vaccine for the H7N9 Influenza Virus MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine. It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary,...
Growth platforms(2) sales increased 8.6%(3) PARIS, May 2, 2013 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2013 Change (reported) Change (CER) Net sales EUR8,059m -5.3% -2.8% Business net income(1) EUR1,613m -33.5% -28.8% Business EPS(1) EUR1.22 -33.3% -29.0% In order to facilitate an understanding of our...
BEIJING, April 30, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccine products in China, announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2012 on April 30, 2013. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section. The Company will provide a hard copy of its complete audited...
Flublok is the world's first FDA approved recombinant protein vaccine for the prevention of seasonal influenza LONDON, April 30, 2013 /PRNewswire/ -- Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease in individuals aged 18-49 years to gain U.S. FDA approval....
Ensuring hospital staff safety is paramount to hospital operational sustainability during a pandemic. WASHINGTON, April 29, 2013 /PRNewswire/ -- The outbreak of the new H7N9 bird flu in China, which the WHO called "an unusually dangerous virus for humans," should be an incentive for a renewed look at infection control procedures and pandemic readiness, which includes proper protection of health care staff. Taiwanese news agency CNA is reporting that "3 hospital staff show symptoms...
